Numis Securities Ltd upgraded shares of Hikma Pharmaceuticals Plc (LON:HIK) to a buy rating in a report issued on Thursday morning. Numis Securities Ltd currently has GBX 1,300 ($17.10) price objective on the stock.

Several other research analysts have also commented on HIK. Morgan Stanley lowered Hikma Pharmaceuticals Plc to an equal weight rating and lowered their price target for the stock from GBX 2,050 ($26.96) to GBX 1,600 ($21.04) in a research report on Wednesday, August 2nd. Peel Hunt reiterated a hold rating and issued a GBX 2,150 ($28.28) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 17th. Jefferies Group LLC reduced their price objective on Hikma Pharmaceuticals Plc from GBX 1,390 ($18.28) to GBX 1,045 ($13.74) and set a hold rating on the stock in a research note on Monday, August 21st. Goldman Sachs Group, Inc. (The) cut Hikma Pharmaceuticals Plc to a neutral rating and reduced their price objective for the company from GBX 2,600 ($34.20) to GBX 1,310 ($17.23) in a research note on Tuesday, August 22nd. Finally, Citigroup Inc. reiterated a neutral rating and issued a GBX 1,350 ($17.76) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 24th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of GBX 1,321.91 ($17.39).

Hikma Pharmaceuticals Plc (LON HIK) traded down GBX 31.50 ($0.41) on Thursday, hitting GBX 960.50 ($12.63). The stock had a trading volume of 1,404,662 shares, compared to its average volume of 823,245. Hikma Pharmaceuticals Plc has a 1-year low of GBX 934 ($12.28) and a 1-year high of GBX 2,346 ($30.86).

ILLEGAL ACTIVITY NOTICE: “Hikma Pharmaceuticals Plc (HIK) Stock Rating Upgraded by Numis Securities Ltd” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.watchlistnews.com/hikma-pharmaceuticals-plc-hik-stock-rating-upgraded-by-numis-securities-ltd/1700841.html.

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.